Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Scienture Holdings, Inc.

Get SEC filing alerts via email and in your feed for Scienture Holdings, Inc.

SCNX

Scienture Holdings, Inc.

About Scienture Holdings, Inc.

Scienture Holdings, Inc. develops and commercializes pharmaceutical products targeting CNS and CVS diseases. Its core activities include developing novel treatments for hypertension, migraine, pain, and thrombosis, with a focus on innovative formulations and biosimilars. The company partners with contract manufacturers and collaborates with regulatory agencies to bring FDA-approved medicines to healthcare providers and patients, emphasizing research, development, and strategic licensing in a competitive pharmaceutical market.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Scienture Holdings, Inc.

1
1
Scienture Holdings, Inc. Scienture Holdings Reports 449% Revenue Increase but Faces Net Loss and Liquidity Concerns

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Scienture Holdings, Inc. Scienture Holdings Reports Fiscal Year 2025 Results with Revenue Growth and Strategic Shift

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Scienture Holdings, Inc. Scienture Holdings Reports 810% Revenue Increase but Faces Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Scienture Holdings, Inc. Scienture Holdings Reports No Revenue and Increased Losses in Latest Financial Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Scienture Holdings, Inc. Scienture Holdings Reports $10,258 Revenue in Q1 2025, Significant Loss Reduction

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Scienture Holdings, Inc. Scienture Holdings Reports $9.1 Million Net Loss and Significant Revenue Decline in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Scienture Holdings, Inc. Scienture Holdings Reports Significant Financial Changes, Including 83% Revenue Decline and 337% Operating Expense Increase in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments